75000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 75010 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 75020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 75030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 75040 - Statement - Condensed Consolidated Statements of Stockholders' (Deficit) Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 75050 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Organization and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Agreements with Royalty Pharma link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Research and Development Arrangements link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Balance Sheet Components link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Organization and Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Organization and Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Agreements with Royalty Pharma (Tables) link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Research and Development Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Balance Sheet Components (Tables) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Organization and Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Organization and Significant Accounting Policies - Schedule of Customers Accounted for Product Revenue (Detail) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Net Loss Per Share - Instruments Excluded from the Computation of Diluted Net Loss Per Share (Detail) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Agreements with Royalty Pharma - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Agreements with Royalty Pharma - Schedule of Future Minimum Payments of Principal Amount with Repayment (Detail) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Agreements with Royalty Pharma - Summary of Changes of Fair Value of Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Agreements with Royalty Pharma - Schedule Represents Allocation of Transaction Consideration on a Relative Fair Value Basis to the Liability and the Common Stock (Detail) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Agreements with Royalty Pharma - Schedule of Future Minimum Payments under Loan Agreement (Detail) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Agreements with Royalty Pharma - Schedule of Future Minimum Payments under Loan Agreement (Detail) 2 link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Agreements with Royalty Pharma - Summary of Changes of Fair Value of Derivative Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Agreements with Royalty Pharma - Additional Information (Detail 1) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Research and Development Arrangements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Fair Value Measurements - Summary of Fair Value of Financial Assets Consists of Cash Equivalents and Investments Classified as Available-for-sale Securities Measured on Recurring Basis (Detail) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Fair Value Measurements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Balance Sheet Components - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Balance Sheet Components - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Balance Sheet Components - Accounts Receivable, Net (Detail) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Balance Sheet Components - Schedule of Inventories (Detail) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Balance Sheet Components - Summary of Accrued Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - Debt - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995845 - Disclosure - Debt - Schedule of Interest Cost Relating to 2031 Notes, 2027 Notes and 2026 Notes (Detail) link:presentationLink link:calculationLink link:definitionLink 995855 - Disclosure - Debt - Schedule of Future Minimum Payments under 2031 Notes, 2027 Notes and 2026 Notes (Detail) link:presentationLink link:calculationLink link:definitionLink 995865 - Disclosure - Debt - Schedule of Future Minimum Payments under 2031 Notes, 2027 Notes and 2026 Notes (Detail) 2 link:presentationLink link:calculationLink link:definitionLink 995875 - Disclosure - Debt - Schedule of Future Minimum Payments under 2031 Notes, 2027 Notes and 2026 Notes (Detail) 3 link:presentationLink link:calculationLink link:definitionLink 995885 - Disclosure - Stockholders' Equity - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995895 - Disclosure - Stockholders' Equity - Summary of Stock Options and Restricted Stock Units Granted (Detail) link:presentationLink link:calculationLink link:definitionLink 995905 - Disclosure - Stockholders' Equity - Summary of Warrants Outstanding to Purchase Shares of Common Stock (Detail) link:presentationLink link:calculationLink link:definitionLink 995915 - Disclosure - Stockholder's Equity - Summary of Stock-Based Compensation Expense (Detail) link:presentationLink link:calculationLink link:definitionLink 995925 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995935 - Disclosure - Subsequent Event - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink Term Loan Tranche One Tranche Four And Tranche Six [Member] Term loan tranche one tranche four and tranche Ssix. Term Loan Tranche 1, Tranche 4 and Tranche 6 [Member] Concentration Risk Type [Axis] Summary of Changes of Fair Value of Derivative Liabilities Schedule of Derivative Liabilities at Fair Value [Table Text Block] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Balance Sheet Location Statement of Financial Position Location, Balance [Domain] Percentage Of Incremental For Annual Net Sales Percentage of incremental for annual net sales. Percentage of incremental for annual net sales Class of warrant or right exercised. Class Of Warrant Or Right Exercised Warrants Exercised Ending balance Beginning balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Additional consideration Additional consideration amount paid Additional Consideration Amount paid Additional consideration amount paid. Non-cash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Term loans, net Long-term Debt, Excluding Current Maturities, Total Long-Term Debt, Excluding Current Maturities Plan Name Plan Name [Axis] Percentage of aggregate investment subsequent market approval Percentage Of Aggregate Investment Subsequent Market Approval Percentage of aggregate investment subsequent market approval. Equity [Abstract] Entity Current Reporting Status Entity Current Reporting Status US Government Agencies Debt Securities [Member] U.S. Government agency securities Operating expenses: Operating Expenses [Abstract] Fair Value Measurements Using Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Investment in non-marketable equity security Investment, Policy [Policy Text Block] Product and Service Product and Service [Axis] Fair Value by Liability Class Fair Value by Liability Class [Domain] Customer B [Member] Customer B. Document Fiscal Period Focus Document Fiscal Period Focus January two thousand twenty issuance date. January Two Thousand Twenty Issuance Date [Member] January 2020 [Member] Entity Shell Company Entity Shell Company Other accrued expenses Other Accrued Liabilities, Current Upfront payment received Upfront Payment Received Upfront payment received. Segment Reporting, Policy [Policy Text Block] Segment Information Cash and Cash Equivalents, at Carrying Value, Ending Balance Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Cash and Cash Equivalent Schedule of Future Minimum Payments under Loan Agreement Schedule of Maturities of Long-Term Debt [Table Text Block] Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Axis] RP loan agreement. R P Loan Agreement [Member] RP Loan Agreement [Member] Arrangement consideration of debt transaction Arrangement Consideration of Debt Transaction Arrangement consideration of debt transaction Initial measurement [Member] Initial measurement. Initial measurement Common stock, shares issued Issuance of common stock under at-the-market offering, net of issuance costs, shares Common Stock, Shares, Issued, Total Purchase of common stock shares Asset Class Asset Class [Domain] Statement [Table] Statement [Table] Term Loan Tranche 4 and 5 [Member] Term Loan Tranche Four and Five [Member] Term loan tranche four and five. Right-of-use assets recognized in exchange for operating lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Increase in operating lease right-of-use asset Stock options, Weighted average date fair value per share Per unit weighted average grant date fair value Stock options, Weighted average grant date fair value per share Option grant prices as percentage of the fair market value of the common stock Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Statement [Line Items] Statement [Line Items] Effect of Change in Accounting Estimate, Type [Axis] Customer A [Member] Customer A. Modification in 2024 RPI transactions Modification In Two Thousand and Twenty Four R P I Transactions Modification in 2024 RPI transactions. Entity Filer Category Entity Filer Category Reclassification, Comparability Adjustment [Policy Text Block] Reclassification of prior periods Liabilities and Equity Total liabilities and stockholders' deficit Thereafter Long Term Debt Maturities Repayments Of Principal After Year Four Long term debt maturities repayments of principal after year four. Debt Instrument [Line Items] Debt Instrument [Line Items] Payables and Accruals [Abstract] Long-Term Debt, Current Maturities, Total Long-Term Debt, Current Maturities Current portion of convertible and long-term debt Long-Term Debt, Maturity, Year Three 2029 Number of instalments description Debt Instrument, Frequency of Periodic Payment Net Product Receivables Net product receivables. Net product receivables Term loan tranche four. Term Loan Tranche Four [Member] Term Loan Tranche 4 [Member] Capitalized Overhead in Inventory [Member] Capitalized overhead in inventory. Subsequent Event [Line Items] Sanofi License Agreement [Member] Sanofi license agreement. Sanofi License Agreement [Member] Options to Purchase Common Stock [Member] Research and Development Revenues [Member] Research And Development [Member] Research and development. Proceeds from Convertible Debt Proceeds from issuance of convertible debt, net Upfront payment Upfront payment. Milestone payment Milestone payment. Long-term investments Debt Securities, Available-for-Sale, Noncurrent Investment carrying value Geographical Geographical [Domain] Asset-Backed Securities [Member] Asset-backed securities [Member] Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items] Liabilities related to revenue participation right purchase agreements. Liabilities Related To Revenue Participation Right Purchase Agreements [Line Items] R P C K 586 R P A R P I I C A V And R P O M Loan Agreement [Member] RP CK-586 RPA RPI Icav And RP OM loan agreement. RP CK-586 RPA, RPI ICAV and RP OM Loan Agreement [Member] Milestone Revenues [Member] Milestone [Member] Milestone member. Additional Paid in Capital, Common Stock, Ending Balance Additional Paid in Capital, Common Stock, Beginning Balance Additional paid-in capital Additional Paid in Capital, Common Stock Initial Recognition [Member] Initial recognition. License and Milestone Revenues [Member] License and milestone revenues. Number of RPDF equal quarterly Number of RPDF Equal Quarterly Number of RPDF equal quarterly. Restricted cash equivalents Restricted Cash Equivalent Restricted Cash Equivalents, Total Clinical and preclinical costs Accrued Clinical And Preclinical Costs Current Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical and preclinical costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Ulacamten RPA [Member] Ulacamten RPA. Ulacamten RPA Vesting Vesting [Domain] Stock options, Grants Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Rule 10b51 Arr Modified Flag Rule 10b51 Arr Modified Flag. Percentage of payment to fund of research and development cost Percentage Of Payment To Fund Of Research And Development Cost Percentage of payment to fund of research and development cost. Term Loan Tranche 1 Tranche 4 Tranche 5 Tranche 6 and Tranche 7 [Member] Term Loan tranche 1 tranche 4 tranche 5 tranche 6 and tranche 7. Liability [Member] Liability [Member] Earnings Per Share, Basic, Total Earnings Per Share, Basic Net loss per share - basic Repayment of term loans Repayments of Long-Term Debt Repayments of Long-term Debt, Total RP Ulacamten RPA, RPI ICAV [Member] RP Ulacamten RPA, RPI ICAV. RP Ulacamten RPA, RPI ICAV [Member] Nonrefundable payment obligation. Nonrefundable Payment Obligation Nonrefundable payment obligation Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Foreign currency translation adjustments Total current liabilities Liabilities, Current Debt Conversion Description Debt Conversion Description [Axis] Accounts receivable Increase (Decrease) in Accounts Receivable Adjustments to reconcile net loss to net cash used in operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Summary of Changes of the Fair Value of Liabilities Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Finished goods Inventory, Finished Goods, Net of Reserves Term Loan Tranche 2 and Tranche 3 [Member] Term loan tranche 2 and tranche 3. Subject to minimum floor amount Subject to Minimum Floor Amount Subject to a minimum floor amount. Contractual interest expense Interest Expense, Debt, Excluding Amortization Liabilities related to revenue participation right purchase agreements, net ending balance Liabilities related to revenue participation right purchase agreements, net beginning balance Liabilities related to revenue participation right purchase agreements, net Liabilities Related To Revenue Participation Right Purchase Agreements, Net Liabilities related to revenue participation right purchase agreements, net. Equity, Attributable to Parent [Abstract] Stockholders' deficit Entity Small Business Entity Small Business RP Ulacamten RPA [Member] Rp ulacamten rpa. Increase (Decrease) in Accrued Liabilities, Total Accrued and other liabilities Increase (Decrease) in Accrued Liabilities Scenario 4 [Member] Scenario Four [Member] Scenario 4. Research and Development [Abstract] Accumulated deficit Retained Earnings (Accumulated Deficit), Ending Balance Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Total Accumulated deficit incurred Retained Earnings (Accumulated Deficit) Number of tranche Number Of Tranche Number of tranche. Public offering price per share Sale of Stock, Price Per Share Percentage of change of control occur of principal amount of loan Percentage Of Change Of Control Occur Of Principal Amount Of Loan Percentage of change of control occur of principal amount of loan. Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Project [Domain] Amendment Flag Amendment Flag Product and Service Product and Service [Domain] New drug application. New Drug Application [Member] New Drug Application [Member] Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' DEFICIT Entity Address, Postal Zip Code Entity Address, Postal Zip Code Net cash provided by (used in) operating activities Net cash provided by (used in) operating activities Net cash used in operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description Common Stock [Member] Common Stock [Member] The maximum contractual term of stock option grants. Term To Grant Nonstatutory Stock Options And Incentive Stock Options Term to grant nonstatutory stock options and incentive stock options Long-Term Debt, Maturity, Year One 2027 Amortization of debt discount Amortization of Debt Discount (Premium) Payment of RPDF for ten business days after OM approval date Payment Of RPDF For Ten Business Days After The OM Approval Date Payment of RPDF for ten business days after the OM approval date. Share-Based Payment Arrangement, Amount Capitalized Stock based compensation capitalized into inventories Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Debt instrument effective interest rate Debt Instrument, Interest Rate, Effective Percentage Entity Address, Address Line One Entity Address, Address Line One Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Convertible notes, percentage of conversion price Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Earnings Per Share [Abstract] Supplemental cash flow disclosures: Supplemental Cash Flow Information [Abstract] Equity Securities without Readily Determinable Fair Value, Amount Equity investment without readily determinable fair value Term loan, maturity year Line of Credit Facility, Expiration Period Balance Sheet Location Statement of Financial Position Location, Balance [Axis] RP OM RPA [Member] R P O M R P A [Member] RP OM RPA. Operating lease right-of-use assets Operating lease, right-of-use assets Operating Lease, Right-of-Use Asset Purchases of investments Payments to Acquire Debt Securities, Available-for-Sale Royalty Liability [Table] Royalty Liability [Table] Royalty liability. OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total Unrealized loss on available-for-sale securities, net Unrealized loss on available-for-sale securities, net Inventory Current and Noncurrent Inventory current and noncurrent. Total current and long-term inventories Class of Warrant or Right [Axis] Document Type Document Type Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Percentage of milestone payment aggregate investment Percentage Of Milestone Payment Aggregate Investment Percentage of milestone payment aggregate investment. Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Entity Central Index Key Entity Central Index Key Debt Conversion Expense Debt conversion expense. Debt conversion expense Debt conversion expense Convertible Senior Notes Due2031 [Member] Convertible Senior Notes Due2031. 2031 Notes [Member] Net (decrease) increase in cash, cash equivalents, and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Subsequent Event Type [Domain] Scenario 3 [Member] Scenario Three [Member] Scenario 3. New employee. New Employee [Member] New Employee [Member] Maximum offering price of common stock under At The Market agreement Maximum Offering Price of Common Stock Under At The Market Agreement Maximum offering price of common stock under At The Market Agreement Total shares Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Percentage of amount payable of principal amount Percentage Of Amount Payable Of Principal Amount Percentage of amount payable of principal amount. Customer C [Member] Customer C. Cash and Cash Equivalents and Investments [Member] Cash And Cash Equivalents And Investments [Member] Cash and cash equivalents and investments. Common stock per share Common stock, par value Common Stock, Par or Stated Value Per Share Share-Based Payment Arrangement, Tranche One [Member] Tranche One [Member] Change in earnings per share. Change In Earnings Per Share Change in Reduction in net loss per share Change in net loss per share Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Debt Securities, Available-for-sale, Total Fair Value Debt Securities, Available-for-Sale Net carrying amount of the convertible notes Convertible notes, net Convertible Notes Net Convertible notes, net Realized Investment Gains (Losses) Realized Investment Gains (Losses), Total Realized gain on investment, net Milestone revenues recognized Milestone Revenue Recognized Milestone revenue reecognized. Schedule Of Inventory Current and Noncurrent [Table Text Block] Schedule of inventory current and noncurrent. Schedule of Inventories Debt Instruments [Abstract] Exercise of stock options, shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Debt Disclosure [Abstract] Wendell Wierenga [Member] Wendell Wierenga. Total accrued liabilities Accrued liabilities Accrued Liabilities, Current Stock Issued During Period, Value, Restricted Stock Award, Gross Vesting of restricted stock units, value Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Current Fiscal Year End Date Current Fiscal Year End Date Debt Instrument [Table] Schedule of Long-Term Debt Instruments [Table] RP CK-586 RPA, RPI ICAV. RP CK-586 RPA, RPI ICAV [Member] RP CK-586 RPA, RPI ICAV [Member] Document Quarterly Report Document Quarterly Report Repayment of convertible debt Repayment of convertible debts Repayment of convertible debts Convertible Notes Noncurrent Convertible notes, net Convertible notes noncurrent. Consideration fair value allocation Consideration Fair Value Allocation Consideration fair value allocation. Entity Address, State or Province Entity Address, State or Province Royalty Purchase Finance Trust Agreement [Member] Royalty purchase finance trust agreement. Stock Issued During Period, Value, Conversion of Convertible Securities Exercise of warrants, net, value Term loan, remaining borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity Convertible notes, consecutive trading days Debt Instrument, Convertible, Threshold Consecutive Trading Days Comprehensive loss Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Summary of significant accounting policies. Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Liabilities related to revenue participation right purchase agreement, net. Liabilities Related To Revenue Participation Right Purchase Agreement Net Liabilities related to revenue participation right purchase agreements, net Three point five percentage of net sales payable for excess of annual worldwide net sales. Three Point Five Percentage Of Net Sales Payable For Excess Of Annual Worldwide Net Sales 3.5% of net sales payable for excess of annual worldwide net sales Class of Warrant or Right [Domain] Geographical Geographical [Axis] Convertible notes, percentage of last reported sale price of common stock Debt Instrument Convertible Threshold Less Than Percentage Of Stock Price Trigger Debt instrument convertible threshold less than percentage of stock price trigger. Rule 10b5-1 Trading Plan Seven [Member] Rule 10b5-1 Trading Plan Seven. Rule 10b5-1 Trading Plan Seven [Member] Interest accretion Interest Accretion Interest accretion. Repayable loan percentage to principal amount Including interest and other fees Repayable Loan Percentage to Principal Amount Including Interest and Other Fees Repayable loan percentage to principal amount Including interest and other fees. Summary of Stock-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Exercise of stock options, value Stock Issued During Period, Value, Stock Options Exercised Schedule of Customers Accounted for Product Revenue Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block] Research and Development Arrangements Collaborative Arrangement Disclosure [Text Block] Other Comprehensive Income (Loss), Net of Tax [Abstract] Other comprehensive (loss) gain: Performance Shares [Member] Performance Stock Units [Member] Percentage of cash payments of principal amount Percentage Of Cash Payments Of Principal Amount Percentage of cash payments of principal amount. Rule 10b5-1 Trading Plan Thirteen [Member] Rule 10b5-1 Trading Plan Thirteen. Rule 10b5-1 Trading Plan Thirteen [Member] Long-term Investments [Member] Long Term Investment [Member] Long term investment. Long-Term Debt, Fair Value Fair value of long term debt Estimated fair value of long term debt Subsequent Event [Member] Subsequent Event [Member] Long-Term Debt, Maturity, Remainder of Fiscal Year 2026 remainder Deferred Revenue, Current Deferred Revenue, Current, Total Deferred revenue Other assets Other Assets, Noncurrent Investment carrying value Less: Unamortized interest and loan costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Less: Unamortized debt issuance costs on the convertible notes Debt Securities, Available-for-Sale, Current Debt Securities, Available-for-sale, Current, Total Short-term investments Antidilutive Securities Antidilutive Securities [Axis] Share-based compensation arrangement by share based payment award award vesting rights percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Awards vesting percentage Total interest expense recognized Interest Expense, Debt Total recognized expense Debt instrument, unamortized debt issuance cost Debt Instrument, Unamortized Discount, Total Debt instrument, unamortized discount Debt Instrument, Unamortized Discount Schedule of Activity within Liabilities Related to Sale of Future Royalties Schedule Of Activity Within Liabilities Related To Sale Of Future Royalties Table [Text Block] Tabular disclosure of activity within liabilities related to sale of future royalties. Andrew Callos [Member] Andrew Callos. AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) [Member] Customer [Domain] Derivative Liability Ending balance Beginning balance Derivative Liability Derivative Liability, Total Additional embedded derivatives recognized Preferred Stock, Value, Issued, Ending Balance Preferred Stock, Value, Issued, Beginning Balance Preferred Stock, Value, Issued, Total Preferred Stock, Value, Issued Preferred stock Selling, general and administrative Selling, General and Administrative Expense Selling, General and Administrative Expense, Total Convertible notes, maturity date Debt Instrument, Maturity Date Liabilities related to RPI transactions fair value. Liabilities related to RPI Transactions measured at fair value Liabilities Related To R P I Transactions FairValue Minimum [Member] Minimum [Member] Potential additional payments receivable Potential Milestone Payments And Royalties Receivable Potential milestone payments and royalties receivable. Financial Instrument [Axis] Current assets: Assets, Current [Abstract] Interest Expense, Other Interest and other expense, net Interest and other expense, net Accounting For The License And Collaboration Agreements In China [Member] Accounting for the license and collaboration agreements in China. Accounting for the License and Collaboration Agreements in China [Member] Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Summary of Stock Options and Restricted Stock Units Granted Schedule Of Share Based Compensation Stock Options and Restricted Stock Units Granted [Table Text Block] Schedule Of Share Based Compensation Stock Options and Restricted Stock Units Granted [Table Text Block] Summary of Fair Value of Financial Assets Consists of Cash Equivalents and Investments Classified as Available-for-sale Securities Measured on Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Current liabilities: Liabilities, Current [Abstract] Rule 10b5-1 Trading Plan Ten [Member] Rule 10b5-1 Trading Plan Ten. Rule 10b5-1 Trading Plan Ten [Member] Stock issued during Period Value Inducted Conversion of Convertible Notes Stock issued during period value inducted conversion of convertible notes. Induced conversion of convertible notes Term loan tranche three. Term Loan Tranche Three [Member] Term Loan Tranche 3 [Member] Tranche 1 and Tranche 6 [Member] Tranche One and Tranche Six [Member] Tranche One and Tranche Six [Member] Rule 10b5-1 Trading Plan Five [Member] Rule 10b5-1 Trading Plan Five. Rule 10b5-1 Trading Plan Five [Member] Beginning Balance, shares Ending Balance, shares Shares, Outstanding Accounts Receivable, after Allowance for Credit Loss, Current Total accounts receivable, net Accounts receivable Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Schedule of Accounts Receivable, Net Commitments and contingencies Commitments and Contingencies Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Ending Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Beginning Balance Restricted stock units, Weighted average date fair value per share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Restricted stock units, Weighted average grant date fair value per share General and Administrative [Member] General and Administrative Expense [Member] Effect of Change in Accounting Estimate, Type [Domain] Forecast [Member] Scenario Forecast Interest receivable and amortization on investments Interest Receivable And Amortization On Investments Interest receivable and amortization on investments. Concentration Risk Benchmark [Axis] Rule 10b5-1 Trading Plan Six [Member] Rule 10b5-1 Trading Plan Six. Rule 10b5-1 Trading Plan Six [Member] Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Long-Term Debt, Maturity, Year Two 2028 2019 Term Loan [Member] Two Thousand Nineteen Term Loan [Member] Two Thousand Nineteen Term Loan [Member] Amounts unpaid for purchases of property and equipment Capital Expenditures Incurred but Not yet Paid Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Long-term Debt, Type Long-Term Debt, Type [Domain] Weighted Average Number of Shares Outstanding, Basic, Total Weighted Average Number of Shares Outstanding, Basic Weighted-average number of shares used in computing net loss per share - basic Scenario [Axis] Rule 10b5-1 Trading Plan [Member] Rule 10b5-1 Trading Plan. Commercial based milestone payments Commercial Based Milestone Payments Commercial based milestone payments. Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Less: Interest Interest Payable Proceeds from Issuance of Private Placement Proceeds from issuance of common stock related to private placement, net of issuance costs Subsequent Events [Text Block] Subsequent Events Convertible notes, type of equity security issued Debt Instrument, Convertible, Type of Equity Security Long-Term Debt Future minimum payments Term Loan, net Long term debt APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Beginning Balance Ending Balance Equity, Attributable to Parent Total stockholders' deficit Preferred stock, par value Preferred Stock, Par or Stated Value Per Share Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Statement of Stockholders' Equity [Abstract] RP Aficamten Liability RP Aficamten RPA, RPI ICAV. R P Aficamten R P A R P I I C A V [Member] RP Aficamten RPA, RPI ICAV [Member] Debt Instrument Convertible Covenant Two [Member] Debt Instrument Convertible Covenant Two [Member] Debt Instrument Convertible Covenant Two [Member] Debt Instrument Convertible Covenant Two. Share-Based Payment Arrangement, Tranche Two [Member] Tranche Two [Member] Collaboration Revenues [Member] Collaboration revenues. Rule 10b5-1 Trading Plan Nine [Member] Rule 10b5-1 Trading Plan Nine. Rule 10b5-1 Trading Plan Nine [Member] Use of Estimates Use of Estimates, Policy [Policy Text Block] Liabilities related to revenue participation right purchase agreements. Liabilities Related To Revenue Participation Right Purchase Agreements [Table] Liabilities Related To Revenue Participation Right Purchase Agreements [Table] Additional carrying value Additional Carrying Value Additional carrying value. Underwriters Option [Member] Over-Allotment Option [Member] Fair Value Measurements Fair Value Disclosures [Text Block] Project [Axis] Summary of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Debt Instrument, Name Debt Instrument, Name [Domain] Liability Related to Sale of Future Royalties [Line Items] Royalty Liability [Line Items] Royalty liability. Long-Term Debt, Maturity, Year Four 2030 Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration] Inventories, long-term Inventory, Noncurrent Inventory, Noncurrent, Total Inventories, long-term Plan Name Plan Name [Domain] Cash payment under royalty agreement Payments For Future Royalties The amount of cash paid for future royalties. Interest expense Interest Expense, Operating and Nonoperating Interest Expense, Operating and Nonoperating, Total Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Receivable [Policy Text Block] Accounts Receivable, net Capitalized Overhead in Inventories [Member] Capitalized overhead in inventories. At The Market Offering [Member] At The Market Offering [Member] At the Market Offering. Term loan tranche two. Term Loan Tranche Two [Member] Term Loan Tranche 2 [Member] Term Loan Tranche 6 [Member] Term loan tranche 6. Credit Facility Credit Facility [Axis] Proceeds From R P I Transactions Agreement Proceeds from RPI transactions agreement. Proceeds from RPI Transactions Award vesting right Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights Warrants Outstanding Outstanding warrants Class of Warrant or Right, Outstanding Other Noncurrent Assets [Member] Other Assets [Member] O H C M [Member] oHCM [Member] oHCM. Convertible Debt, Fair Value Disclosures Convertible debt, fair value Schedule of Allocated Consideration Schedule Of Allocated Consideration Table [Text Block] Schedule of allocated consideration. Rights granted. Rights Granted [Member] Rights Granted [Member] Entity Address, City or Town Entity Address, City or Town Stock Issued During Period Value Restricted Stock Award Net Stock issued during period value restricted stock award net. Vesting of restricted stock units, net of taxes withheld, value RP Aficamten RPA and RP OM RPA. Rp Aficamten Rpa and RP OM RPA [Member] RP Aficamten RPA and RP OM RPA [Member] Cost of goods sold Cost of Goods Sold Cost of goods sold. Number of reportable segments Number of Reportable Segments Security Exchange Name Security Exchange Name Bayer License Agreement [Member] Bayer license agreement. Credit Facility Credit Facility [Domain] Future minimum payments Long-Term Debt, Gross Weighted-average effective rate of interest Debt, Weighted Average Interest Rate Debt Conversion, Name Debt Conversion, Name [Domain] Percentage of discount rates for fair values of derivative liabilities Percentage of Discount Rates for Fair Values of Derivative Liabilities Percentage of discount rates for fair values of derivative liabilities. Concentration Risk Type [Domain] Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Inventory, Net Inventories Total inventories, current Total cash, cash equivalents, and restricted cash as reported within our condensed consolidated statement of cash flows Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Ending Balance Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Beginning Balance Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activity Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] RP Aficamten Liability [Member] Royalty Agreements Terms [Member] Royalty agreements terms. Statistical Measurement Statistical Measurement [Domain] Unamortized debt discount amortization period Debt Instrument, Convertible, Remaining Discount Amortization Period Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise Price Total current assets Assets, Current Allocated share based compensation expense Share-Based Payment Arrangement, Expense Percentage of annual worldwide net sales. Percentage Of Annual Worldwide Net Sales Percentage of net sales payable Document Period End Date Document Period End Date Investment in non-marketable equity security Investment in Non-Marketable Equity Security Investment in non-marketable equity security. Investment in non-marketable equity security Title and Position [Axis] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Robert A. Harrington [Member] Robert A. Harrington. Tranche One Tranche Four Tranche Five and Tranche Six [Member] Tranche One Tranche Four Tranche Five and Tranche Six Term Loan Tranche 1 Tranche 4 Tranche 5 and Tranche 6 [Member] Convertible notes, sinking fund Debt Instrument, Sinking Fund Payment Statement of Financial Position [Abstract] Restricted Stock Units [Member] Restricted Stock Units (RSUs) [Member] Receivables, Net, Current [Abstract] Accounts receivable, net Revenue [Policy Text Block] Net Product Revenue Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Vesting Vesting [Axis] Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract] Public Offering [Member] Public offering. Public Offering [Member] Rule 10b5-1 Trading Plan Eleven [Member] Rule 10b5-1 Trading Plan Eleven. Rule 10b5-1 Trading Plan Eleven [Member] Potential Milestone Payments And Royalties Unearned And Receivable Upon Achievement Of Milestone Potential milestone payments and royalties unearned and receivable upon achievement of milestone. Potential milestone payments and royalties unearned and receivable upon achievement of milestone Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Liabilities Total liabilities Liabilities Financial Instruments [Domain] Increase (Decrease) in Deferred Revenue Deferred revenue Development and commercial milestone received. Development and Commercial Milestone Received Development and commercial milestone received Restricted cash Restricted Cash Restricted Cash, Total Imputed rate of interest on unamortized portion of liability Imputed Rate Of Interest On Unamortized Portion Of Liability Imputed rate of interest on unamortized portion of liability. Term Loan Tranche 6 and 7 [Member] Tranche Six and Tranche Seven [Member] Tranche six and tranche seven. Scenario 2 [Member] Scenario Two [Member] Scenario 2. Weighted Average Number of Shares Outstanding, Diluted, Total Weighted Average Number of Shares Outstanding, Diluted Weighted-average number of shares used in computing net loss per share - diluted Entity File Number Securities Act File Number Cover [Abstract] Stock issue during period private placement value. Stock Issue During Period Private Placement Value Issuance of common stock upon private placement, value Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Change in fair value Change in fair value of derivative liabilities Change in fair value of derivative liabilities Derivative, Gain (Loss) on Derivative, Net Derivative, Gain (Loss) on Derivative, Net, Total Rule 10b5-1 Trading Plan Three [Member] Rule 10b5-1 Trading Plan Three. Rule 10B51Trading Plan Three [Member] Revenue Benchmark [Member] Scenario [Domain] U.S. Treasury Securities [Member] US Treasury Securities [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Number of authorized shares of common stock available for issuance Sale of Stock [Domain] General and administrative General and Administrative Expense General and Administrative Expense, Total Subsequent Event [Table] Change in fair value Change in fair value resulted in loss Change in fair value derivative liabilities Derivative, Fair Value Hedge, Included in Effectiveness, Gain (Loss) Vesting percentage realized upon one-year anniversary of grant date. Percentage Of Options Grant To New Employees Percentage of options grant to new employees Convertible notes, initial conversion price Debt Instrument, Convertible, Conversion Price Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Stock Issued During Period, Shares, Conversion of Convertible Securities Common Shares Issued upon Exercise of Warrants Exercise of warrants, net, share Percentage of net sales payable for excess of annual worldwide net sales Percentage Of Net Sales Payable For Excess Of Annual Worldwide Net Sales Percentage of net sales payable for excess of annual worldwide net sales Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period RP OM Loan Agreement and Ulacamten RPA [Member] Rp om loan agreement and ulacamten rpa. RP OM Loan Agreement and Ulacamten RPA [Member] Four point five percentage of net sales payable for maximum annual worldwide net sales. Four Point Five Percentage Of Net Sales Payable For Maximum Annual Worldwide Net Sales 4.5% of net revenue to be receivable from annual worldwide net sales Convertible notes, redemption description Debt Instrument, Redemption, Description Organization Business Description And Accounting Policies Policy [Text Block] Business Description And Accounting Policies Policy. Payment of RPDF for first anniversary after of OM approval date Payment Of RPDF For First Anniversary Of Om Approval Date Payment of RPDF for first anniversary of OM approval date. Organization and Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] The minimum period of time, subsequent to the current balance sheet date, for which the company believes existing cash, cash equivalents and investments will be sufficient to fund its cash requirements. Cash Requirements Term Cash requirements term Short-term operating lease liabilities Operating lease, short-term lease liability Operating Lease, Liability, Current Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items] Depreciation of property and equipment Depreciation, Depletion and Amortization, Total Depreciation, Depletion and Amortization Document Transition Report Document Transition Report Total operating expenses Operating Expenses Accrued liabilities: Accrued Liabilities, Current [Abstract] Prospective Liability Adjustment Estimate Decreased In Net Loss Per Share Prospective liability adjustment estimate decreased In net loss per share. Prospective liability adjustment estimate decreased In net loss per share Derivative Instrument Detail [Abstract] Research and development Research and Development Expense Research and Development Expense, Total Statement of Cash Flows [Abstract] Issuance of common stock, net of issuance costs, value Stock Issued During Period, Value, New Issues RP Multi Tranche Loan Agreement Derivatives RP Multi Tranche Loan [Member] RP Multi Tranche Loan [Member] RP multi tranche loan. Stockholders' Equity Equity [Text Block] Net Loss Per Share Earnings Per Share [Text Block] Debt Security, Government, Non-US [Member] Foreign government agency securities Net loss Net loss Increase (Decrease) in Inventories Increase (Decrease) in Inventories, Total Inventories Term Loan Tranche Four And Tranche Five [Member] Term Loan Tranche Four And Tranche Five. Term Loan Tranche 4 And Tranche 5 [Member] Purchase Obligation Purchase Obligation, Total Non-cancellable commitments Derivatives, Fair Value [Line Items] ASSETS Assets [Abstract] Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Initial recognition Fair value, measurement with unobservable inputs reconciliation, recurring basis, initial recognition. Initial measurement Increase (Decrease) in Prepaid Expense and Other Assets, Total Prepaid and other assets Increase (Decrease) in Prepaid Expense and Other Assets Non-cash interest expense on liabilities related to revenue participation right purchase agreements Non-cash interest expense on liabilities related to revenue participation right purchase agreement. Non Cash Interest Expense On Liabilities Related To Revenue Participant Right Purchase Agreement Document Fiscal Year Focus Document Fiscal Year Focus Convertible notes, shares issued Debt Conversion, Converted Instrument, Shares Issued Concentration Risk Benchmark [Domain] Cash flows from investing activities: Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Accounts Payable, Current, Total Accounts payable Accounts Payable, Current Shares Issuable Related to the ESSP [Member] Shares Issuable Related to the ESSP [Member] Employee Stock Purchase Plan [Member] Employee stock purchase plan. Research and Development [Member] Research and Development Expense [Member] NonRule 10b51 Arr Modified Flag NonRule 10b51 Arr Modified Flag. Transaction Type [Axis] Convertible notes, principal amount Debt Conversion, Converted Instrument, Amount Schedule of Transactions Consideration Schedule of Consideration of Fair Value Allocation and Fair Value at Issuance or Modification [Table Text Block] Schedule of consideration of fair value allocation and fair value at issuance or modification. Vesting of restricted stock units, net of taxes withheld, shares Stock Issued During Period Shares Restricted Stock Award Net Stock issued during period shares restricted stock award net. Gross proceeds from issuance of private placement Gross Proceeds From Issuance Of Private Placement Gross proceeds from issuance of private placement. Fair Value Disclosures [Abstract] Commitments and Contingencies Disclosure [Abstract] Realization of revenue participation right purchase agreement. Realization of Revenue Participation Right Purchase Agreement [Member] Realization of Revenue Participation Right Purchase Agreement [Member] Rule 10b5-1 Trading Plan Two [Member] Rule 10b5-1 Trading Plan Two. Rule 10B51Trading Plan Two [Member] Term loan, drawn amount Long-Term Line of Credit Long-Term Line of Credit, Total Debt Instrument Debt Instrument [Axis] Derivative Instrument [Axis] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Unamortized/unrecognized stock-based compensation expense related to PSUs Proceeds from sale of products. Proceeds From Sale Of Products Purchased rights to certain revenue streams from net sales in consideration payment Sale of Stock [Axis] Loan commencing, date Loan Commencing, Date Loan commencing, date. Concentration Risk, Percentage Concentration risk, percentage Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Net cash provided by investing activities Private Placement [Member] Private Placement [Member] Title of 12(b) Security Title of 12(b) Security Maximum future development and commercial milestone payments receivable. Maximum Future Development and Commercial Milestone Payments Receivable Maximum future development and commercial milestone payments achievable Corxel Omecamtiv Mecarbil license and collaboration agreement. Corxel Omecamtiv Mecarbil License and Collaboration Agreement [Member] Corxel Omecamtiv Mecarbil License and Collaboration Agreement [Member] Number of Business Activity Number of business activity. Number of business activity Money Market Funds [Member] Money Market Funds [Member] Long-Term Debt, Maturity, after Year Five Thereafter Term Loan Tranche 7 [Member] Term Loan Tranche Seven [Member] Term loan tranche seven. Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] John T. Henderson [Member] John T. Henderson. Debt Instrument, Notes Converted Into Shares Debt instrument, notes converted into shares. Convertible notes, converted into shares Stock issue during period private placement. Stock Issue During Period Private Placement Share Issuance of common stock upon private placement, shares Other non-current liabilities Other Liabilities, Noncurrent Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Proceeds from issuance of common stock under equity incentive and stock purchase plans Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised, Total Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Debt Instrument Convertible Covenant One [Member] Debt Instrument Convertible Covenant One [Member] Debt Instrument Convertible Covenant One [Member] Debt Instrument Convertible Covenant One. Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] 2027 Notes [Member] Convertible senior notes due 2027 member. Convertible Senior Notes Due 2027 [Member] Rule 10b5-1 Trading Plan One [Member] Rule 10b5-1 Trading Plan One. Rule 10B51Trading Plan One [Member] Derivative Liability Settlement Derivative liability settlement. Settlement Stock issued during period, value, issued for services Stock Issued During Period, Value, Issued for Services Measurement Frequency Measurement Frequency [Domain] Statement of Income Location, Balance [Axis] Trading Symbol Trading Symbol Liabilities, Fair Value Adjustment Change in fair value of liabilities related to RPI Transactions Change in fair value of liabilities related to RPI Transactions Subsequent Event Type [Axis] Employee-related Liabilities, Current, Total Compensation related Employee-related Liabilities, Current Cash flows from financing activities: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Fair Value, Measurements, Recurring [Member] Fair Value, Recurring [Member] Initial stock option vesting period. Period From Percentage Of Stock Option Vested Period from percentage of stock option vested Non-cash interest expense on liabilities related to revenue participation right purchase agreements Non-Cash Interest Expenses on Liabilities Related to Revenue Participation Right Purchase Agreements Non-cash interest expenses on liabilities related to revenue participation right purchase agreements Rule 10b5-1 Trading Plan Fourteen [Member] Rule 10b5-1 Trading Plan Fourteen. Rule 10b5-1 Trading Plan Fourteen [Member] nHCM. N H C M [Member] nHCM [Member] Percentage Of Net Sales Payable For Incremental Annual Worldwide Net Sales Percentage of net sales payable for incremental annual worldwide net sales. Percentage of net sales payable for incremental annual worldwide net sales Additional Paid-in Capital [Member] Equity Components [Axis] Non-cash lease expense Non Cash Lease Expense Non cash lease expense. Existing employee. Existing Employee [Member] Existing Employee [Member] Interest and other income, net Nonoperating Income (Expense) Nonoperating Income (Expense), Total Additional consideration amount paid of first pivotal clinical trail Additional Consideration Amount Paid of First Pivotal Clinical Trail Additional consideration amount paid of first pivotal clinical trail. Equity Component Equity Component [Domain] Cash and Cash Equivalents and Investments [Member] Asset Class [Axis] Convertible notes, interest rate Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate Public Offering [Member] IPO [Member] Collaboration Cost of Sales Collaboration cost of sales. Collaboration cost of sales Stock Issued During Period, Shares, Employee Stock Purchase Plans Issuance of common stock under Employee Stock Purchase Plan, shares Customer [Axis] B. Lynne Parshall [Member] B. Lynne Parshall. Aggregate principal amount remaining Debt Instrument Remaining Face Amount Debt instrument remaining face amount. Maximum [Member] Maximum [Member] Liabilities at fair value Liabilities, Fair Value Disclosure Liabilities, Fair Value Disclosure, Total Number Of Authorized Shares Available For Issuance Number of authorized shares available for issuance. Number of authorized shares available for issuance Statistical Measurement Statistical Measurement [Axis] Change In Non Cash Interest Expense and Net Loss Change in non cash interest expense and net loss. Change in non-cash interest expense and net loss Common Stock, Value, Issued, Ending Balance Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Total Common Stock, Value, Issued Common stock Agreements with Royalty Pharma Agreements with Royalty Pharma [Text Block] Agreements with Royalty Pharma. Increase in number of authorized shares reserved for issuance. Increase In Number Of Authorized Shares Reserved For Issuance Increase in number of authorized shares reserved for issuance Repayment of finance lease liabilities Finance Lease, Principal Payments Tranche 1, Tranche 4 and Tranche 6 [Member] Tranche One Tranche Four and Tranche Six [Member] Tranche One Tranche Four and Tranche Six. Cantor [Member] Cantor Fitzgerald & Co. [Member] Cantor Fitzgerald & Co. [Member] Gross proceeds from issuance of common stock Gross Proceeds From Issuance Of Common Stock Gross proceeds from issuance of common stock. Repayable loan percentage to principal amount Repayable Loan Percentage to Principal Amount Repayable loan percentage to principal amount. Stock issued during Period Shares Inducted Conversion of Convertible notes Stock issued during period shares inducted conversion of convertible notes. Induced conversion of convertible notes, shares Amortization of debt issuance costs Amortization of Debt Issuance Costs Amortization of issuance costs Percentage of probability of default of derivative liabilities Percentage of Probability of Default of Derivative Liabilities Percentage of probability of default of derivative liabilities. Schedule of Cash, Cash Equivalents and Restricted Cash Equivalents [Table Text Block] Schedule of cash, cash equivalents and restricted cash equivalents. Reconciliation of Cash, Cash Equivalents, and Restricted Cash Research Collaboration [Member] Research Collaboration. Term Loan Tranche 1 Tranche 4 and Tranche 5 [Member] Term loan tranche 1, tranche 4 and tranche 5. Taxes paid related to net share settlement of equity awards Taxes paid related to net share settlement of equity awards Payment, Tax Withholding, Share-Based Payment Arrangement Oxford and Silicon Valley Bank [Member] Oxford And Silicon Valley Bank [Member] Oxford and Silicon Valley Bank. Non-cash interest expense recognized Non-cash interest expense on liability related to sale of future royalties Non Cash Interest Expense Related To Sale Of Future Royalties Non cash interest expense related to sale of future royalties. U.S. Treasury Securities Backed Repurchase Agreements [Member] U.S. Treasury securities backed repurchase agreements. Term loan tranche five. Term Loan Tranche Five [Member] Term Loan Tranche 5 [Member] Entity Registrant Name Entity Registrant Name Debt Debt Disclosure [Text Block] Amended ATM Facility [Member] Amended ATM Facility [Member] Amended ATM facility. Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Customer Concentration Risk [Member] 2024 RPI Transactions [Member] Two Thousand Twenty Four R P I Transaction [Member] Two Thousand Twenty Four R P I Transactions. Subsequent Events [Abstract] Debt Securities, Available-for-sale, Gain (Loss), Total Credit losses on debt securities Debt Securities, Available-for-Sale, Gain (Loss) Fair Value, Measurements, Recurring [Member] Measurement Frequency [Axis] Proceeds from issuance of common stock, net of issuance costs Net proceeds of issuance of common stock Proceeds from issuance of common stock related to at-the-market offering, net of issuance costs Schedule of Product Information [Table Text Block] Schedule of Customers Accounted for Product Revenue Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Net Product Revenue [Member] Net product revenue. Percentage Of Annual Net Sales Percentage of annual net sales. Percentage of annual net sales Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Convertible notes, conversion description Debt Instrument, Convertible, Terms of Conversion Feature Liability Class Liability Class [Axis] Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income Accumulated other comprehensive (loss) income Schedule of Interest Cost Relating to Notes Convertible Debt [Table Text Block] Payments to Acquire Property, Plant, and Equipment, Total Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Restricted stock units, Grants Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Total assets Assets Inventory, Policy [Policy Text Block] Inventories Percentage Of Prior To Market Aggregate Investment Percentage of prior to market aggregate investment. Percentage of prior to market aggregate investment Income Statement [Abstract] Corporate Obligations [Member] Corporate Obligations [Member] Corporate obligations. Potential Milestone Payments And Royalty Earned potential milestone payments and royalty earned. Potential additional milestone earned Rule 10b5-1 Trading Plan Four [Member] Rule 10b5-1 Trading Plan Four. Rule 10B51Trading Plan Four [Member] Summary of significant accounting policies. Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Issuance of common stock, net of issuance costs, shares Shares of Common Stock Issuance of shares of common stock Restricted Stock and Performance Units [Member] Restricted Stock And Performance Units [Member] Restricted stock and performance units member. Earnings Per Share, Diluted, Total Earnings Per Share, Diluted Net loss per share - diluted Accounts payable Increase (Decrease) in Accounts Payable, Trade Title and Position [Domain] City Area Code City Area Code New Loan and Security Agreement [Member] Loan And Security Agreement [Member] Loan and security agreement. Convertible notes, principal amount Principal amount of original loan Debt Instrument, Face Amount Convertible notes, principal amount Term loan, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Payment for repurchase of convertible notes. Payment For Repurchase Of Convertible Notes Payment associated with convertible notes Induced Conversion of Convertible Debt Expense Inducement Loss RP Stock Purchase Agreement [Member] Royalty Pharma Stock Purchase Agreement [Member] Royalty pharma stock purchase agreement. Royalty Liability [Abstract] Royalty liability. Percent of royalty on net sale Percent Of Royalty On Sale Percent of royalty on sale. Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of common stock under Employee Stock Purchase Plan, value Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Agreements with Royalty Pharma [Abstract] Agreements with Royalty Pharma. Derivative liabilities measured at fair value Derivative Liability, Current Initial measurement Property, Plant and Equipment, Net, Ending Balance Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Total Property and equipment, net Property, Plant and Equipment, Net Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Cash, cash equivalents, and restricted cash, beginning of period Cash, cash equivalents, and restricted cash, end of period Total cash, cash equivalents, and restricted cash as reported within our consolidated statement of cash flows Operating loss Operating loss Operating Income (Loss) Maximum percentage commission to be paid on gross proceedings under at the market agreement Maximum Percentage Commission to Be Paid On Gross Proceedings Under At The Market Agreement Maximum percentage commission to be paid on gross proceedings under at the market agreement Accumulated Deficit [Member] Retained Earnings [Member] Rule 10b5-1 Trading Plan Eight [Member] Rule 10b5-1 Trading Plan Eight. Rule 10b5-1 Trading Plan Eight [Member] Transaction [Domain] Warrant Expiration Period Warrant expiration period. Expiration Date Share-based Payment Arrangement, Noncash Expense, Total Share-Based Payment Arrangement, Noncash Expense Stock-based compensation expense Long-term operating lease liabilities Operating lease, long-term lease liability Operating Lease, Liability, Noncurrent Fair Value Measurements Using Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Net cash provided by financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation 2004 Plan [Member] Two Thousand And Four Equity Incentive Plan [Member] 2004 Equity Incentive Plan. Collaboration Receivables Collaboration receivables. Collaboration receivables Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Summary of Warrants Outstanding to Purchase Shares of Common Stock Derivative Contract [Domain] Instruments Excluded from the Computation of Diluted Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Contingent liabilities Estimated Litigation Liability CRL Option [Member] CRL Option [Member] CRL Ooption. Entity Interactive Data Current Entity Interactive Data Current Statement of Income Location, Balance [Domain] Increase in number of authorized shares available for issuance Increase In Number Of Authorized Shares Available For Issuance Increase in number of authorized shares available for issuance. Cash flows from operating activities: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Non-cash interest expense related to debt Paid-in-Kind Interest Rule 10b5-1 Trading Plan Twelve [Member] Rule 10b5-1 Trading Plan Twelve. Rule 10b5-1 Trading Plan Twelve [Member] RP OM Loan Agreement And RP Ulacamten RPA [Member] RP OM Loan Agreement and RP Ulacamten RPA. Schedule of Maturities of Notes Schedule Of Maturities Of Convertible Debt Table [Text Block] Schedule​ of maturities​ of convertible debt table ​text​ block. Other non-current liabilities Increase (Decrease) in Other Noncurrent Liabilities Change in fair value Change in fair value of liabilities Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Change in fair value Term loan, current borrowing capacity Line of Credit Facility, Current Borrowing Capacity RP Aficamten RPA [Member] RP Aficamten RPA. Scenario 1 [Member] Scenario One [Member] Scenario 1. Entity Tax Identification Number Entity Tax Identification Number Revenues: Revenues [Abstract] Long-term Debt, Type Long-Term Debt, Type [Axis] Change in Accounting Method Accounted for as Change in Estimate [Member] Change in Accounting Estimate [Member] Edward M. Kaye [Member] Edward M. Kaye. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale Maturities of investments Effect of exchange rate changes on cash Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Local Phone Number Local Phone Number Corxel License Agreements [Member] Corxel license agreements. Other Liabilities, Current, Total Other current liabilities Other Liabilities, Current China [Member] CHINA Two thousand twenty two royalty pharma transactions. Two Thousand Twenty Two Royalty Pharma Transactions [Member] 2022 Royalty Pharma Transactions [Member] RP OM Liability RPOM Liability [Member] Royalty Purchase Finance Trust Agreement [Member] Operating lease liabilities Increase Decrease In Operating Lease Liabilities Operating lease liabilities. Convertible notes, trading days Debt Instrument, Convertible, Threshold Trading Days Revenue from Contract with Customer, Excluding Assessed Tax, Total Revenue from Contract with Customer, Excluding Assessed Tax Total revenues Revenues Term Loan Tranche 1 [Member] Term Loan Tranche One [Member] Term loan tranche one. Prospective Liability Adjustment Estimate Decreased In non Cash Interest Expense Prospective liability adjustment estimate decreased in non cash interest expense. Prospective liability adjustment estimate decreased in non cash interest expense Prior period reclassification adjustment Prior Period Reclassification Adjustment Inventory, Net [Abstract] Corxel Aficamten license and collaboration agreement. Corxel Aficamten License and Collaboration Agreement [Member] Corxel Aficamten License and Collaboration Agreement [Member] Debt Instrument, Repurchased Face Amount Repurchase of principal amount of original loan Commercial Paper [Member] Commercial Paper [Member] Shares available for grant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Cash, cash equivalents and investments Cash, Cash Equivalents, and Short-Term Investments Cash, Cash Equivalents, and Short-Term Investments, Total RP OM Loan Agreement [Member] RP OM Loan Agreement [Member] RP OM Loan Agreement. Entity Emerging Growth Company Entity Emerging Growth Company 2026 Notes [Member] Convertible Notes 2026 [Member] Convertible Senior Notes Due2026 [Member] Convertible senior notes due 2026 member.